Genpharmasec Ltd (GENPHARMA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Genpharmasec Ltd on NSE and BSE, with an AI summary of each filing.
Statement of deviation or variation in the use of proceeds of Rights Issue for the Quarter ended 30th September, 2026.
Others (Uncategorized) · 03 Nov 2026, 11:16 pm
Genpharmasec Confirms Nil Deviation in Rights Issue Proceeds Utilization for Sep'26 Quarter Genpharmasec Limited reported zero deviation or variation in utilizing proceeds from its Rights Issue (allotted 21st Feb'24) for the quarter ended 30th Sep'26. Out of Rs. 4,845.05 Lakhs total raised, key allocations include Rs. 1,650.00 Lakhs fully utilized for working capital, Rs. 1,443.58 Lakhs fully utilized to acquire shares in Derren Healthcare Private Limited, Rs. 1,138.47 Lakhs for general corporate purposes, and Rs. 25.00 Lakhs for issue expenses. Additionally, Rs. 289.00 Lakhs has been utilized toward debt repayment out of an allocated Rs. 588.00 Lakhs.
Outcome of the Meeting of Board of Directors held on Tuesday, 03rd November, 2026.
Change in Management · 03 Nov 2026, 11:08 pm
Genpharmasec Approves Subsidiary Divestment and CS Resignation Genpharmasec’s board approved the full divestment of its wholly owned subsidiary, Clinigenome India Private Limited, to Micro Genomics India Private Limited. Clinigenome contributed ₹100.47 Lakhs (0.72%) to consolidated turnover and had a net worth of ₹(154.41) Lakhs in the last financial year. The non-related-party transaction is slated for completion on or before 31st Mar'27, with financial consideration to be determined. Additionally, Company Secretary and Compliance Officer Hardik Makwana resigned, effective 16th Nov'26, to pursue external opportunities. Unaudited results for the period ended 30th Sep'26 were approved.
Unaudited Standalone & consolidated Financial Result of the company for the quarter & half year ended 30th September 2026.
Financial Result · 03 Nov 2026, 11:02 pm
Genpharmasec Reports Strong Q2 Results and Divestment of Clinigenome India Genpharmasec reported consolidated revenue of ₹8,565.82 lakh for the quarter ended 30th Sep'26, up significantly from ₹3,263.71 lakh YoY and ₹4,971.03 lakh QoQ. Consolidated net profit swung to ₹102.92 lakh versus a net loss of ₹117.62 lakh in the prior-year period. In addition, the Board approved the complete divestment of wholly owned subsidiary Clinigenome India Private Limited to Micro Genomics India Private Limited by 31st Mar'27. Company Secretary Hardik Makwana tendered his resignation, effective 16th Nov'26.
Outcome of the Meeting of Board of Directors held on Tuesday, 03rd November, 2026.
Outcome · 03 Nov 2026, 10:55 pm
Genpharmasec Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakhs) ■ Revenue: 8,566 (+162.5% YoY | +72.3% QoQ) ■ EBITDA: 164 (Loss to Profit YoY | +71.4% QoQ) ■ EBITDA Margin (%): 1.9 (Loss to Profit YoY | -1 bps QoQ) ■ PAT: 125 (Loss to Profit YoY | +381.9% QoQ) ■ EPS (INR): 0.01 (Loss to Profit YoY) Genpharmasec Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakhs) Segmental Performance Pharmaceutical Trading ■ Revenue: 8,155 (+165.5% YoY | +73.5% QoQ) ■ EBIT: 282 (+93.3% YoY | +28.2% QoQ) ■ EBIT Margin (%): 3.5 (-129 bps YoY | -122 bps QoQ) Laboratory Testing ■ Revenue: 0.0 (-100.0% YoY) ■ EBIT: -39.9 (-6.3% YoY | -36.7% QoQ) ■ EBIT Margin (%): 0.0 (Loss to Profit YoY) Manufacturing & Processing ■ Revenue: 411 (+172.5% YoY | +51.3% QoQ) ■ EBIT: -40.0 (+75.8% YoY | +68.0% QoQ) ■ EBIT Margin (%): -9.7 (+9981 bps YoY | +3627 bps QoQ)
Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve 1. To consider and approve Un-audited ....
Intimation · 03 Nov 2026, 5:30 am
Genpharmasec Schedules Board Meeting to Approve Q2 Results Genpharmasec Limited has scheduled a Board of Directors meeting on 3rd Nov'26 to consider and approve the un-audited standalone and consolidated financial results, along with the Limited Review Report, for the quarter and half-year ended 30th Sep'26. In compliance with SEBI insider trading regulations, the trading window for dealing in company securities has been closed from 1st Oct'26 and will reopen 48 hours following the formal declaration of the financial results.
Intimation under regulation 30 - Change of name of Subsidiary of the company.
Others (Uncategorized) · 14 Oct 2026, 8:22 pm
Genpharmasec Renames Middle East Subsidiary Pursuant to Revised DMCC Naming Regulations Genpharmasec Limited has changed the name of its subsidiary from GENPHARMASEC MIDDLE EAST DMCC to GENPHARMASEC MIDDLE EAST FZCO, effective 9th Oct'26. The modification was executed in compliance with updated naming conventions mandated by the Dubai Multi Commodities Centre (DMCC), requiring all registered entities to adopt the suffix "FZCO".
Disclosure of Voting Results and Scrutinizers report of the 34th Annual General Meeting held on 29th September, 2026.
Annual General Meeting · 30 Sept 2026, 8:20 pm
Submission of Proceeding of the 34th Annual General Meeting of the Member of the Genpharmasec Ltd held on Tuesday, 29th September, 2026.
Annual General Meeting · 29 Sept 2026, 8:29 pm
Annual Report for Financial Year 2025-26.
Others (Uncategorized) · 07 Sept 2026, 6:29 pm
Notice of 34th Annual General Meeting of the company to be held on September 29, 2026.
Annual General Meeting · 07 Sept 2026, 6:13 pm
Outcome of the Meeting of Board of Directors held on Wednesday, 02nd September, 2026.
Change in Management · 02 Sept 2026, 9:22 pm
Genpharmasec Board Approves 34th AGM Date and Director Re-appointment Genpharmasec Limited’s board approved scheduling its 34th AGM on 29th Sep'26 via video conferencing. Share transfer books will close from 23rd Sep'26 to 29th Sep'26. Key resolutions include re-appointing Mr. Sohan Chaturvedi as Whole Time Director for a three-year term effective 26th Apr'27, pending shareholder approval. The board also approved advances, loans, and guarantees under Section 185 of the Companies Act, requiring shareholder consent. Finally, the FY25-26 Annual Report was adopted, with the E-voting cut-off date set for 22nd Sep'26.
Outcome of the Meeting of Board of Directors held on Wednesday, 02nd September, 2026.
Outcome · 02 Sept 2026, 9:19 pm
Genpharmasec Board Approves Section 185 Loans and WTD Re-appointment Genpharmasec Ltd's Board approved the re-appointment of Sohan Chaturvedi as Whole Time Director for a three-year term, effective 26th Apr'27. Crucially, the Board authorized advancing loans and providing guarantees or securities under Section 185 of the Companies Act, pending shareholder approval. The company scheduled its 34th AGM for 29th Sep'26 via video conferencing, establishing a book closure period from 23rd Sep'26 to 29th Sep'26. Additionally, the Board adopted the FY26 Annual Report and set 22nd Sep'26 as the cut-off date for AGM e-voting eligibility.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajesh Sadhwani & PACs
Acquisition/ Disposal of Shares · 02 Sept 2026, 4:09 pm
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajesh Sadhwani
Acquisition/ Disposal of Shares · 31 Aug 2026, 5:34 pm
Genpharmasec Promoter Increases Stake Through Open Market Purchase Promoter Rajesh Sadhwani acquired 50,00,000 equity shares (0.90% stake) of Genpharmasec Ltd. via an open market purchase on 28 Aug'26. Following the transaction, his individual shareholding increased from 13.18% to 14.09%. The total promoter and PAC (Persons Acting in Concert) holding in the company, including Sneha Sadhwani's stake, rose from 29.98% to 30.88%. The disclosure was made under SEBI's takeover regulations.
Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2026 ,inter alia, to consider and approve 1. To Fix the Day, Date, Time ....
Intimation · 28 Aug 2026, 4:32 pm
Regarding Recent Agreement with Amneal Healthcare Private Limited
Press Release · 13 Aug 2026, 10:29 pm
Genpharmasec Enters Super Stockist Agreement with Amneal Healthcare Genpharmasec Limited has entered a non-exclusive Super Stockist agreement with Amneal Healthcare Private Limited (AHPL) as of 13 Aug'26. Under the agreement, Genpharmasec will distribute products manufactured by AHPL and its third-party partners to wholesalers and retailers. AHPL has committed to providing a minimum annual sales value of approximately INR 75 Crores for each calendar year. This partnership significantly expands Genpharmasec's distribution capabilities and market presence, aiming for sustained growth by offering a wider range of high-quality healthcare products.
Statement of deviation or variation in the use of proceeds of Rights Issue for the Quarter ended 30th June, 2026.
Others (Uncategorized) · 11 Aug 2026, 9:51 pm
Genpharmasec: No Deviation in Rights Issue Proceeds Utilization for Q1FY27 Genpharmasec confirmed no deviation in utilizing its Rs. 4,845.05 Lakhs rights issue proceeds for the quarter ended 30th Jun'26. The funds, raised on 21st Feb'24, were used as intended. Key allocations include Rs. 1,443.58 Lakhs for acquiring Derren Healthcare, Rs. 1,650 Lakhs for working capital, Rs. 1,138.47 Lakhs for general corporate purposes, and Rs. 289 Lakhs for debt repayment out of a planned Rs. 588 Lakhs. The Audit Committee reviewed and found no variations in fund use.
Unaudited Standalone & Consolidated Financial Results of the company for the quarter ended 30th June, 2026.
Financial Result · 11 Aug 2026, 9:38 pm
Genpharmasec Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 4,971 (+312.8% YoY | -10.3% QoQ) ■ EBITDA: 95.8 (+2.0% YoY | -51.9% QoQ) ■ EBITDA Margin (%): 1.9 (-588 bps YoY | -167 bps QoQ) ■ PAT: 26.0 (-78.6% YoY | -82.5% QoQ) ■ EPS (INR): 0.00 (-100.0% YoY | -100.0% QoQ) Genpharmasec Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) Segmental Performance Pharmaceuticals ■ Revenue: 4,478 (+283.7% YoY | -13.3% QoQ) ■ EBIT: 222 (+24.8% YoY | -28.5% QoQ) ■ EBIT Margin (%): 5.0 (-1031 bps YoY | -105 bps QoQ) Laboratory Testing ■ Revenue: 0.0 ■ EBIT: -29.2 (+33.5% QoQ) ■ EBIT Margin (%): 0.0 Manufacturing & Processing ■ Revenue: 272 (+630.2% YoY | -27.8% QoQ) ■ EBIT: -125 (-202.2% YoY | -277.4% QoQ) ■ EBIT Margin (%): -46.0 (+6512 bps YoY | -3719 bps QoQ) Unallocable ■ Revenue: 221 ■ EBIT: -2.5 (-337.5% QoQ) ■ EBIT Margin (%): -1.1
Outcome of the Meeting of Board of Directors held on Tuesday, 11th August, 2026.
Outcome · 11 Aug 2026, 9:32 pm
Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve 1. To consider and approve Un-audited ....
Intimation · 11 Aug 2026, 5:30 am
Genpharmasec Board Meeting Set for 11th Aug'26 to Approve Q1 Results Genpharmasec Ltd. has scheduled a Board of Directors meeting on 11th Aug'26 to consider and approve its un-audited standalone and consolidated financial results for the quarter ended 30th Jun'26. In compliance with SEBI insider trading regulations, the trading window for directors and designated persons has been closed from 1st Jul'26 and will reopen 48 hours after the financial results are declared. The company will also consider any other business with the permission of the Chairman during the meeting.
Statement of deviation or variation in the use of proceeds of Rights issue for the Quarter ended 31st March, 2026.
Others (Uncategorized) · 21 May 2026, 11:10 pm
Genpharmasec: No Deviation in Rights Issue Fund Utilization for Q4 FY26 Genpharmasec confirmed no deviation in using the Rs 4,845.05 lakh raised from its Feb'24 Rights Issue for the quarter ended 31 Mar'26. Funds were utilized as stated in the offer, with Rs 1,443.58 lakh used for acquiring Derren Healthcare and Rs 1,650.00 lakh for working capital. Additionally, Rs 289.00 lakh was used for debt repayment out of a planned Rs 588.00 lakh. General corporate purposes and issue expenses were also fully funded as planned. The utilization was reviewed by the Audit Committee.
Audited Standalone & Consolidated Financial Results of the company for the Quarter and Financial year Ended 31st March, 2026.
Financial Result · 21 May 2026, 11:05 pm
Genpharmasec FY26 Audited Results: Revenue Up 277%, PAT Rises 95% YoY Genpharmasec reported strong FY26 audited standalone results. Revenue grew 277% YoY to ₹13,621.88 lakhs, while PAT increased 95% YoY to ₹544.96 lakhs. For Q4 FY26, revenue was ₹5,328.22 lakhs with a PAT of ₹231.81 lakhs. The Board approved the results on 21 May'26 and re-appointed M/s. Abhishek M Agrawal & Co. as Internal Auditor for FY27. Statutory auditors issued an unmodified opinion. Consolidated FY26 PAT stood at ₹56.01 lakhs on revenue of ₹14,309.47 lakhs.
Outcome of the Meeting of Board of Directors held on Thursday, May 21, 2026.
Outcome · 21 May 2026, 10:56 pm
Genpharmasec Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 5,543 (+295.6% YoY | +39.2% QoQ) ■ EBITDA: 199 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 3.6 (Loss to Profit YoY | Loss to Profit QoQ) ■ PAT: 123 (Loss to Profit YoY | Loss to Profit QoQ) ■ EPS (INR): 0.02 (Loss to Profit YoY | Loss to Profit QoQ)
Genpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve 1. To consider, approve & take ....
Intimation · 21 May 2026, 5:30 am
Genpharmasec Sets Board Meeting for Q4 and FY26 Results Genpharmasec Limited (BSE: 531592) has scheduled a Board of Directors meeting on 21 May'26 to consider and approve its audited standalone and consolidated financial results for the quarter and year ended 31 Mar'26. In accordance with SEBI regulations, the trading window for designated persons has been closed from 01 Apr'26 and will reopen 48 hours after the results are declared. This meeting is crucial for assessing the company's full-year financial performance and fourth-quarter trends.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 14 Apr 2026, 9:15 pm
Genpharmasec Not Classified as a Large Corporate Under SEBI Framework Genpharmasec Ltd. (Scrip: 531592) informed the BSE on 14 Apr'26 that it does not fall under the Large Corporate (LC) framework defined by SEBI circulars. The company confirmed it is not obligated to raise funds via debt securities as mandated for LCs. As of 31 Mar or 31 Dec (as applicable), the company reported outstanding borrowings of ₹0.00 Cr and had no credit rating. Consequently, the mandatory borrowing requirements for LCs do not apply to the company.